Faron announces R&D Day in February 2018

Faron Pharmaceuticals Ltd

("Faron" or the "Company")

Faron announces R&D Day in February 2018

TURKU - FINLAND, 14 December 2017 - Faron Pharmaceuticals Ltd ("Faron") (LON: FARN), the clinical stage biopharmaceutical company, announces plans to host an R&D Day on Wednesday, 21 February 2018, at Panmure Gordon's offices, One New Change, London, EC4M 9AF. The event will provide an opportunity to hear about the Company, its R&D strategy and pipeline developments, with a focus on Clevegen, Faron's second wholly-owned pipeline product approaching the start of Phase I/II development in 2018.

Clevegen is a novel anti-Clever-1 antibody, which causes changes in the immune environment of solid tumours by switching immune suppressive M2 macrophages to immune active M1 macrophages. Based on this unique mechanism of action, promising pre-clinical data and human ex vivo data, Clevegen could have potential in a broad range of indications, including immuno-oncology, chronic infections and vaccination enhancement.

The R&D event will provide an update on Clevegen's manufacturing, regulatory and scientific progress, in addition to an update on the clinical development plan. The Phase I/II trial will target patients with liver, melanoma, ovarian and pancreatic cancer as part of an adaptive protocol design, which is currently under review by regulators, with feedback anticipated in early 2018.

Faron will also provide an update on Traumakine, its lead wholly-owned product for the treatment of moderate to severe Acute Respiratory Distress Syndrome (ARDS) following the completion of recruitment in the Phase III INTEREST trial, and for which the top-line data are expected to become available in H1 2018.

For further information on the R&D day, or to register for the event, please contact Consilium Strategic Communications at faron@consilium-comms.com or telephone +44 (0)20 3709 5700.

For more information please contact:

Faron Pharmaceuticals Ltd

Dr Markku Jalkanen, Chief Executive Officer

investor.relations@faron.com 

Consilium Strategic Communications

Mary-Jane Elliott, Chris Welsh, Philippa Gardner, Lindsey Neville

Phone: +44 (0)20 3709 5700

E-mail: faron@consilium-comms.com

Westwicke Partners, IR (US)

Chris Brinzey

Phone: 01 339 970 2843

E-Mail: chris.brinzey@westwicke.com

Panmure Gordon (UK) Limited, Nomad and Broker

Freddy Crossley (Corporate Finance)

Tom Salvesen (Corporate Broking)

Phone: +44 207 886 2500

About Faron Pharmaceuticals Ltd

Faron (AIM:FARN) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline focusing on acute organ traumas, vascular damage and cancer immunotherapy. The Company's lead candidate Traumakine, to prevent vascular leakage and organ failures, is currently the only treatment for Acute Respiratory Distress Syndrome (ARDS) undergoing Phase III clinical trials and in 2017 received advice from US FDA to proceed directly to BLA submission following completion of EU and Japanese Phase III studies. There is currently no approved pharmaceutical treatment for ARDS. An additional European Phase II Traumakine trial is underway for the Rupture of Abdominal Aorta Aneurysm ("RAAA"). Faron's second candidate Clevegen is a ground breaking pre-clinical anti-Clever-1 antibody. Clevegen has the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development. This novel macrophage-directed immuno-oncology switch called Tumour Immunity Enabling Technology ("TIET") may be used alone or in combination with other immune checkpoint molecules for the treatment of cancer patients. Faron is based in Turku, Finland. Further information is available at  www.faron.com